Cantor Fitzgerald Reiterates Overweight Rating for Prenetics Global (NASDAQ:PRE)

Prenetics Global (NASDAQ:PRE)‘s stock had its “overweight” rating reaffirmed by investment analysts at Cantor Fitzgerald in a note issued to investors on Thursday,Benzinga reports. They presently have a $9.00 target price on the stock. Cantor Fitzgerald’s price target indicates a potential upside of 50.25% from the stock’s current price.

Prenetics Global Trading Up 1.0 %

Shares of PRE stock opened at $5.99 on Thursday. Prenetics Global has a fifty-two week low of $2.85 and a fifty-two week high of $7.84. The business’s 50 day moving average price is $5.22 and its 200-day moving average price is $5.09.

About Prenetics Global

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.